Cellarity
United States
- Cambridge, Massachusetts
- 04/10/2022
- Series C
- $121,000,000
Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them. Cellarity is using its platform to design medicines targeting the full cellular and molecular complexity of disease, enabling a quantum leap in the success rate and speed of drug discovery.
- Industry Biotechnology Research
- Website https://cellarity.com/
- LinkedIn https://www.linkedin.com/company/cellarity/
Related People
Fabrice ChouraquiFounder
United States -
ND
I am passionate about changing the practice of medicine and making a difference in patients’ lives. At a time of unprecedented transformation in healthcare, I get my energy from driving the progress of medical sciences and harnessing the fast evolution of digital technologies. For me, it’s all about building a long lasting legacy, developing next generation talents, and inspiring others.
I feel fortunate to have launched many medicines which have changed treatment paradigms in a number of therapeutic areas, including cardiovascular, immunology, neuroscience and oncology. My global experience spans the entire business spectrum, from research and development to commercial leadership, business development and investor communications.
There is still a lot of work to be done on parts of the healthcare value chain so that patients can access the right treatment at the right time. As a Global Pharmaceutical Executive, I am on a mission to ensure that the pharmaceutical industry is an unquestionable bridge between science and the society.
Specialties: Business Transformation, R&D-Commercial Strategy, Investor Communications, Product Launches, Market Access, Digital innovation, Medical Affairs, Clinical Development, Regulatory Submission
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)